Hangzhou Tigermed Consulting Co., Ltd (3347.HK)
- Previous Close
36.350 - Open
36.350 - Bid 35.100 x --
- Ask 35.250 x --
- Day's Range
34.900 - 37.150 - 52 Week Range
22.100 - 65.900 - Volume
1,187,600 - Avg. Volume
2,562,982 - Market Cap (intraday)
49.325B - Beta (5Y Monthly) 0.71
- PE Ratio (TTM)
16.71 - EPS (TTM)
2.100 - Earnings Date Apr 25, 2024
- Forward Dividend & Yield 0.62 (1.69%)
- Ex-Dividend Date May 25, 2023
- 1y Target Est
69.29
Hangzhou Tigermed Consulting Co., Ltd provides contract research organization services in the People's Republic of China and internationally. It operates in Clinical Trial Solutions, and Clinical-related and Laboratory Services segments. The company offers preclinical development services, including medicinal chemistry, compound screening, DMPK, safety and toxicology, bioanalytical, and formulation research and development services; and clinical development services, such as medical writing, clinical monitoring, regulatory affairs, data management and statistical analysis, clinical development strategy, site management, subject recruitment, medical device/ in vitro diagnostics, multi-region clinical trial, and vaccine clinical trial services. It also provides product market research, product marketing strategy, product finalization, product verification, registration strategy planning, marketing application, post-marketing supports, and product upgrade services. In addition, the company offers medical imaging, pharmacovigilance, medical translation, quality assurance, GMP consulting, central laboratories, functional services, EDC system, and call center services; and post-marketing clinical research solutions, such as site identification and selection, central monitoring, project team management, vendor management, and project management services. Hangzhou Tigermed Consulting Co., Ltd was incorporated in 2004 and is headquartered in Hangzhou, the People's Republic of China.
www.tigermedgrp.com9,701
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: 3347.HK
Performance Overview: 3347.HK
Trailing total returns as of 5/17/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 3347.HK
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 3347.HK
Valuation Measures
Market Cap
51.01B
Enterprise Value
46.90B
Trailing P/E
17.26
Forward P/E
17.83
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
4.03
Price/Book (mrq)
1.38
Enterprise Value/Revenue
6.00
Enterprise Value/EBITDA
17.21
Financial Highlights
Profitability and Income Statement
Profit Margin
23.36%
Return on Assets (ttm)
3.45%
Return on Equity (ttm)
7.92%
Revenue (ttm)
7.24B
Net Income Avi to Common (ttm)
1.69B
Diluted EPS (ttm)
2.100
Balance Sheet and Cash Flow
Total Cash (mrq)
7.45B
Total Debt/Equity (mrq)
14.87%
Levered Free Cash Flow (ttm)
247.26M
Research Analysis: 3347.HK
Company Insights: 3347.HK
3347.HK does not have Company Insights